当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Covid-19 and Acute Respiratory Distress Syndrome (ARDS) a Clinical Review

Shuofeng Yuan

The COVID-19 pandemic is a serious problem of the new era. Acute respiratory distress syndrome (ARDS) and respiratory failure are the major lung diseases in COVID-19 patients. Although a COVID-19 vaccine is now available, there is still an urgent need to find potential treatments to reduce the impact of her COVID-19 on already sick patients. Several experimental drugs have been approved by the FDA, but their efficacy and possible side effects are unknown. An increasing number of studies worldwide investigating potential COVID-19-related therapies may help identify effective ARDS treatments. This review article first provides an overview of the immunopathology of ARDS. He then outlines the management of his COVID-19 patient requiring intensive care unit (ICU), focusing on current treatment strategies being evaluated in clinical trials for patients with COVID-19-induced ARDS.